Last reviewed · How we verify
Placebo (x4)
Placebo (x4) is a Small molecule drug developed by Daniel Hägi-Pedersen. It is currently FDA-approved for Used as control in clinical trials across multiple therapeutic areas.
Placebo produces therapeutic effects through patient expectation and the psychobiological placebo response, without active pharmacological ingredients.
Placebo produces therapeutic effects through patient expectation and the psychobiological placebo response, without active pharmacological ingredients. Used for Used as control in clinical trials across multiple therapeutic areas.
At a glance
| Generic name | Placebo (x4) |
|---|---|
| Sponsor | Daniel Hägi-Pedersen |
| Modality | Small molecule |
| Phase | FDA-approved |
Mechanism of action
Placebo works via multiple mechanisms including expectation-induced neurobiological changes, conditioning, and natural disease progression. The effect is mediated by patient belief and contextual factors rather than direct molecular action on disease targets. Placebo responses are well-documented across numerous therapeutic areas and can produce measurable clinical improvements, particularly in subjective symptoms.
Approved indications
- Used as control in clinical trials across multiple therapeutic areas
Common side effects
- Nocebo effects (adverse events attributed to placebo)
Key clinical trials
- A Study of Idazoxan in Healthy Participants (PHASE1)
- Study of Ibrutinib and Rituximab in Treatment Naïve Follicular Lymphoma (PHASE3)
- Preemptive IV Ibuprofen for Neurocognitive Recovery and Analgesic Needs After Inguinal Hernia Surgery (PHASE4)
- Effects of Semaglutide in HIV-Associated Lipohypertrophy (PHASE2)
- A Study to Find a Suitable Dose of Exl-111 for Further Research (PHASE1)
- Fiber and Calcium Absorption in Older Men (PHASE2)
- Ketorolac Effects on Post-operative Pain and Lumbar Fusion (PHASE4)
- D-Cycloserine Augmentation of Intermittent Theta Burst Stimulation (iTBS) in Depression (COGENT) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo (x4) CI brief — competitive landscape report
- Placebo (x4) updates RSS · CI watch RSS
- Daniel Hägi-Pedersen portfolio CI
Frequently asked questions about Placebo (x4)
What is Placebo (x4)?
How does Placebo (x4) work?
What is Placebo (x4) used for?
Who makes Placebo (x4)?
What development phase is Placebo (x4) in?
What are the side effects of Placebo (x4)?
Related
- Manufacturer: Daniel Hägi-Pedersen — full pipeline
- Indication: Drugs for Used as control in clinical trials across multiple therapeutic areas
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing